Menu
Currency
GWAS Study

A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Stacey SN, Sulem P, Jonasdottir A et al.

21946351 PubMed ID
GWAS Study Type
59342 Participants
91 Views
Scroll to explore
Chapter I

Publication Details

Comprehensive information about this research publication

Authors

SS
Stacey SN
SP
Sulem P
JA
Jonasdottir A
MG
Masson G
GJ
Gudmundsson J
GD
Gudbjartsson DF
MO
Magnusson OT
GS
Gudjonsson SA
SB
Sigurgeirsson B
TK
Thorisdottir K
RR
Ragnarsson R
BK
Benediktsdottir KR
NB
Nexø BA
TA
Tjønneland A
OK
Overvad K
RP
Rudnai P
GE
Gurzau E
KK
Koppova K
HK
Hemminki K
CC
Corredera C
FV
Fuentelsaz V
GP
Grasa P
NS
Navarrete S
FF
Fuertes F
GM
García-Prats MD
SE
Sanambrosio E
PA
Panadero A
DJ
De Juan A
GA
Garcia A
RF
Rivera F
PD
Planelles D
SV
Soriano V
RC
Requena C
AK
Aben KK
VR
van Rossum MM
CR
Cremers RG
VO
van Oort IM
VS
van Spronsen DJ
SJ
Schalken JA
PW
Peters WH
HB
Helfand BT
DJ
Donovan JL
HF
Hamdy FC
BD
Badescu D
CO
Codreanu O
JM
Jinga M
CI
Csiki IE
CV
Constantinescu V
BP
Badea P
MI
Mates IN
DD
Dinu DE
CA
Constantin A
MD
Mates D
KS
Kristjansdottir S
AB
Agnarsson BA
JE
Jonsson E
BR
Barkardottir RB
EG
Einarsson GV
SF
Sigurdsson F
MP
Moller PH
ST
Stefansson T
VT
Valdimarsson T
JO
Johannsson OT
SH
Sigurdsson H
JT
Jonsson T
JJ
Jonasson JG
TL
Tryggvadottir L
RT
Rice T
HH
Hansen HM
XY
Xiao Y
LD
Lachance DH
ON
O Neill BP
KM
Kosel ML
DP
Decker PA
TG
Thorleifsson G
JH
Johannsdottir H
HH
Helgadottir HT
SA
Sigurdsson A
SV
Steinthorsdottir V
LA
Lindblom A
SR
Sandler RS
KT
Keku TO
BK
Banasik K
JT
Jørgensen T
WD
Witte DR
HT
Hansen T
PO
Pedersen O
JV
Jinga V
ND
Neal DE
CW
Catalona WJ
WM
Wrensch M
WJ
Wiencke J
JR
Jenkins RB
NE
Nagore E
VU
Vogel U
KL
Kiemeney LA
KR
Kumar R
MJ
Mayordomo JI
OJ
Olafsson JH
KA
Kong A
TU
Thorsteinsdottir U
RT
Rafnar T
SK
Stefansson K
Chapter II

Abstract

Summary of the research findings

To identify new risk variants for cutaneous basal cell carcinoma, we performed a genome-wide association study of 16 million SNPs identified through whole-genome sequencing of 457 Icelanders. We imputed genotypes for 41,675 Illumina SNP chip-typed Icelanders and their relatives. In the discovery phase, the strongest signal came from rs78378222[C] (odds ratio (OR) = 2.36, P = 5.2 × 10(-17)), which has a frequency of 0.0192 in the Icelandic population. We then confirmed this association in non-Icelandic samples (OR = 1.75, P = 0.0060; overall OR = 2.16, P = 2.2 × 10(-20)). rs78378222 is in the 3' untranslated region of TP53 and changes the AATAAA polyadenylation signal to AATACA, resulting in impaired 3'-end processing of TP53 mRNA. Investigation of other tumor types identified associations of this SNP with prostate cancer (OR = 1.44, P = 2.4 × 10(-6)), glioma (OR = 2.35, P = 1.0 × 10(-5)) and colorectal adenoma (OR = 1.39, P = 1.6 × 10(-4)). However, we observed no effect for breast cancer, a common Li-Fraumeni syndrome tumor (OR = 1.06, P = 0.57, 95% confidence interval 0.88-1.27).

2,121 European ancestry cases, 39,614 European ancestry controls

Chapter III

Study Statistics

Key metrics and study information

59342
Total Participants
GWAS
Study Type
Yes
Replicated
2,506 European and other ancestry cases, 15,101 European and other ancestry controls
Replication Participants
European, Other, European
Ancestry
Sweden, U.S., Iceland, Romania, Spain, Hungary, Slovakia, Denmark
Recruitment Country
Chapter IV

AI-Generated Summary

AI-generated by DNAGENICS

Independent AI summary of health and genetic findings from the published study

Important: This summary is AI-generated by DNAGENICS for informational purposes only. It was not created by, affiliated with, or endorsed by the researchers behind the original publication, and is based solely on that published research. It may contain errors or omissions. DNAGENICS disclaims all liability for any inaccuracies or consequences arising from use of this information. Verify all information against the original publication. This is not professional scientific review or medical advice.

AI Summary In Progress

Our AI-generated summary of this publication is being prepared. Please check back soon.